Status | Study |
Withdrawn |
Study Name: Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea Condition: Scleroderma Date: 2016-02-09 Interventions: Drug: Clobetasol ointment, twi |
Terminated |
Study Name: Molecular Effects of Topical Calcipotriene on Morphea Condition: Morphea Localized Scleroderma Date: 2015-03-03 Interventions: Drug: topical calcipotriene 0.005% ointment Affected area will be treated twice daily for 3 months |
Recruiting |
Study Name: Genetic Variants in Linear Localized Scleroderma Condition: Morphea Date: 2014-07-21 Interventions: Other: skin biopsy |
Recruiting |
Study Name: Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma Condition: Localized Scleroderma Date: 2013-09-05 Interventions: Device: Fractional carbon dioxide laser |
Recruiting |
Study Name: Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository Condition: Scleroderma, Localized Morphea Date: 2013-02-25 Interventions: Other: Morphea Other Names: Scleroderma, Localized Scleroderma |
Recruiting |
Study Name: Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea Condition: Scleroderma, Localized Morphea Date: 2013-02-22 Interventions: Procedure: UVA-1 Phototherapy Procedure: P |
Recruiting |
Study Name: Microvascular and Fibrosis Imaging Study Condition: Autoimmune Diseases Sickle Cell Disease Chronic Graft Vers Date: 2012-12-26 Interventions: Other: Acoustic Radiation Force Impulse (ARFI) |
Completed |
Study Name: The CARRA Registry Condition: Juvenile Idiopathic Arthritis Systemic Lupus Erythematosus Date: 2012-09-28 |
Withdrawn |
Study Name: A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy Condition: Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis) Date: 2009-07-09 Interventions: Drug: Rituximab Mabthera, Rituximab 1000 mg I.V. |
Completed |
Study Name: Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea. Condition: Symmetric Limited Morphea. Date: 2008-12-18 Interventions: Other: Medium Dose UVA-1 UVA-1 |